Key points:
- Magentiq Eye Automatic Polyp Detection System (ME-APDS) incorporates advanced AI technologies, including Computer-Aided Polyp Detection (CADe) engine and Deep Neural Networks (DNN) to identify potential mucosal abnormalities during colonoscopies, improving detection rates without altering the video stream.
- Designed to work with standard white-light endoscopy imaging, ME-APDS highlights suspicious areas, aiding in the early detection of colorectal cancer and other gastrointestinal diseases. However, it doesn’t replace histopathological analysis.
- Developed by Magentiq Eye Ltd., the system received FDA pre-market approval on July 25, 2023, marking a significant milestone.
Magentiq Eye Automatic Polyp Detection System
The Magentiq Eye’s Automatic Polyp Detection System (ME-APDS) is a computer-aided detection system used during video colonoscopy procedures to assist endoscopists in identifying lesions like polyps. It processes video frames in real-time, highlighting suspicious areas without altering the video stream.
ME-APDS uses a Computer-Aided Polyp Detection (CADe) engine and Deep Neural Networks (DNN) for real-time lesion detection.
Indications
The system is designed to highlight potential mucosal abnormalities such as polyps during colonoscopy. It is not a diagnostic tool nor a replacement for histopathological sampling. It is limited to use with standard white-light endoscopy imaging.
This AI device was developed by Magentiq Eye Ltd. and received FDA pre-market approval notification on 7/25/2023.
Similar devices are GI Genius from Cosmo Pharma.
Reference
Magentiq Eye Automatic Polyp Detection System (ME-APDS) 510(k) Premarket Notification. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223473
Leave a Reply